Polynovo Ltd. Overview
PolyNovo is an Australian medical-technology company built on NovoSorb®, a proprietary family of fully synthetic, bioabsorbable polyurethane-based polymers that came out of CSIRO research. Its flagship product, NovoSorb® BTM (Biodegradable Temporising Matrix), is a bilayer synthetic dermal scaffold. Clinicians use it to rebuild a vascularised dermis after full-thickness burns, trauma, necrotising infection, oncologic resection and other complex wounds, before definitive skin grafting. A second product, NovoSorb® MTX, is a membrane-free dermal matrix that is broadening the company's reach into deeper, irregular and chronic wounds. NovoSorb® SynPath® is being positioned for the US outpatient market. In FY26 the company generated A$150.0m of total revenue and A$138.4m of commercial sales; the US contributed about 74% of sales. It was EBITDA- and NPAT-positive and free-cash-flow positive. The near-term value drivers are a planned US FDA Premarket Approval (PMA) submission for BTM in full-thickness burns before the end of CY2026, US outpatient reimbursement, MTX adoption and new manufacturing capacity in Port Melbourne.
Company's own description (AR2026, paraphrased). PolyNovo calls itself a Melbourne-headquartered medtech company transforming the management of acute and complex wounds. Its products, NovoSorb® BTM and NovoSorb® MTX, are intended to improve outcomes across a wide range of wound types. The company reports more than 127,000 patients treated in more than 50 countries. Its stated principal activity is developing medical devices from the NovoSorb® polymer. That polymer can be produced as foams, coatings, fibres, plastic structures, films and biologic carriers, and the company claims advantages over competing bioabsorbable polymers in design flexibility, bioabsorption and biocompatibility.
Independent characterisation. PolyNovo is a single-platform, single-franchise advanced wound-care company. In FY26 BTM made up about 91% of commercial sales and MTX about 9%. Its core market is US hospital inpatient burn and trauma surgery. PolyNovo sells a synthetic alternative to (a) collagen/bovine dermal templates, chiefly Integra's dermal regeneration template, (b) cadaveric allograft used as temporary cover, and (c) flap-based reconstruction in some indications. The synthetic chemistry is clinically differentiated by its reported tolerance to bacterial contamination and its lower risk of matrix loss through infection. It also carries no xenogeneic material, and as a fully synthetic product it is easier to manufacture at scale than biologics. On the company's own inventory-based definition, gross margins are in the high 80s to mid 90s per cent.
Revenue model. Almost all revenue is product sales of single-use devices sized by area and thickness, sold per unit to hospitals.
Source: FY26 results presentation (26-Aug-2026); AR2026 Directors' Report. PolyNovo has no subscription or licensing revenue. Management said in FY26 that it intends to build a business-development function to pursue partnering and licensing of NovoSorb® formulations outside its core commercial strengths.
Value chain position. PolyNovo is vertically integrated from polymer synthesis to finished sterile device. Manufacturing is concentrated in Port Melbourne. The company sells directly in Australia, Hong Kong, India, Malaysia, New Zealand, Singapore, the UK and the US, and uses distributors elsewhere: PMI (Germany), Medival (Italy), Woondz (France), Arbor Vitae International (eight Balkan markets) and a Japanese distributor for planned entry into Japan.
Customers and end-markets. The direct customers are hospitals: burn units, trauma centres, plastic and reconstructive surgery, vascular/limb salvage, orthopaedics, general surgery and surgical oncology, plus, increasingly, outpatient and wound-clinic settings. The US had 880+ hospital accounts at FY26, with 200 added during the year. Globally, 252 new hospital accounts were added in FY26. In the US, sales from indications other than large burns grew at a 52.8% three-year CAGR, against 19.1% for large burns and 30.9% for all indications (FY26 presentation). The mix is shifting from episodic, event-driven burn volumes toward more predictable complex-wound procedures.
Strategy
Stated strategy (AR2026 / FY26 investor presentation)
| Pillar | Stated components |
|---|---|
| Scale the Core | Advance leadership in burn care in key markets; grow procedural share in complex wounds; expand access by leveraging the PMA |
| Leverage the Platform | Build, partner and prioritise for growth; shape the next generation of NovoSorb® innovation; progress strategic business development |
| Build a Global Enterprise | Augment the manufacturing footprint; drive accountability through aligned focus; scale globally while protecting culture and values |
| Region | Levers |
|---|---|
| Americas | Submit and capitalise on the PMA; launch SynPath and extend the outpatient presence; increase procedural share in existing accounts; drive MTX adoption |
| EMEA | Build on portfolio versatility across specialties; launch MTX in the UK; accelerate new distributor markets; grow evidence and KOL engagement |
| APAC | Sustain non-burn growth; accelerate MTX in Australia, Hong Kong and NZ; deepen penetration; add dedicated coverage in Malaysia |
The FY26 strategy is titled "Proven Platform. Scaling for Growth." It has three pillars:
FY27 priorities (verbatim themes): (1) secure PMA approval and evidence-based expansion; (2) launch NovoSorb® SynPath® for the US outpatient market; (3) accelerate NovoSorb® MTX adoption; (4) increase innovation velocity and build business-development capability; (5) deliver greater operating leverage and profitability as the business scales.
Regional growth levers (FY26 presentation)
Strategic initiatives in the last 24 months
| Initiative | Timing | Detail / targets |
|---|---|---|
| US PMA for BTM (full-thickness burns) | Submission before end of CY2026 | Clinical Study Report finalised on 12-month data. The submission will include 18-month follow-up. The plan was revised after updated FDA QMS guidance took effect in February 2026, with priority given to validating and documenting manufacturing and supplier processes. |
| US outpatient strategy and SynPath launch | FY27 | Dedicated outpatient team covering marketing, market access, reimbursement and market development. Clinical evidence package submitted to CMS on 31 Oct 2025 to support Medicare coverage of BTM under the skin-substitute LCDs. Company asked CMS to place BTM under SynPath's HCPCS A2006 or issue a new code. An MTX HCPCS application is in preparation. |
| MTX global rollout | FY25–FY27 | Six markets live; UK and EU MDR clearance targeted in FY27; Taiwan, Brazil and Mexico in progress |
| Manufacturing expansion | Aug 2024 to FY27 | New Port Melbourne facility completed; validation ongoing; transition in FY27; A$1.5m machinery capex outstanding |
| R&D reprioritisation | FY26–FY27 | CSO appointed; formal NPD and Portfolio Prioritisation framework; hernia and implant programs under commercial-options review; "indication-first" approach |
| Business-development function | FY27 | New team to pursue partnering and licensing of NovoSorb® formulations and adjacencies |
| Governance renewal | Mar 2025 to Apr 2026 | New Chair, three new directors, separate committees, board skills matrix, new GC/CoSec, policy refresh |
| Remuneration reform | From FY27 | LTI plan introduced; enhanced disclosure |
| Investor communications | Feb 2026 | Interactive investor hub launched; management promises "clarity and consistency" in communication |
| ESG / climate | FY25–FY26 | Full value-chain GHG inventory; AASB S2 gap assessment; carbon-neutral certification (Australian operations) |
| Market entry | FY26–FY27 | BTM registered in 8 new markets in FY26; Japan entry plan progressing with PMDA consultation via a distributor; Mexico registrations under way |
Medium-term targets and guidance
PolyNovo has not issued formal quantitative FY27 revenue or earnings guidance in the materials reviewed. The qualitative guidance is to deliver greater operating leverage and profitability as the business scales and to accumulate cash in FY27 if current trends continue. The last numeric guidance was for 1H FY25 / FY25 (revenue growth of 20–25% and EBITDA growth of 30–35%, per the February 2025 presentation summary). Former CEO Raote had spoken of a 25% growth ambition. Management has also cited a long-term addressable-market aspiration of about A$500 million in revenue (AR2023 context); this is not a current target.
Products & Services
Commercial products (NovoSorb® wound-care franchise)
| Product | Description and key capabilities | Target customer / indications | Regulatory status and launch timing | Pricing model |
|---|---|---|---|---|
| NovoSorb® BTM (Biodegradable Temporising Matrix) | Bilayer synthetic dermal matrix: a biodegradable polyurethane foam scaffold with a temporary sealing membrane. It regenerates the dermis lost through extensive surgery, trauma or burns. Once the matrix is integrated, the wound is closed with a split-thickness skin graft or by secondary intention. Clinicians report strong integration even over poorly vascularised beds such as exposed bone and tendon, and reported tolerance to bacterial contamination. | Burn, trauma, plastic/reconstructive, vascular/limb-salvage, orthopaedic, general and oncologic surgeons; full-thickness burns, necrotising soft-tissue infection, degloving, skin-cancer resections, chronic wounds | Cleared/registered in 50+ countries. US: FDA 510(k) cleared (initial clearance year not re-verified in this dossier); up to 6 mm thickness cleared June 2025. US PMA for an on-label full-thickness burns indication targeted for submission before end of CY2026. Registered in 7 new European countries in FY26 (Latvia, Lithuania, Estonia, Croatia, Slovenia, Albania, Serbia) and in Brazil. | Per-unit device sales to hospitals by size and thickness; list prices not publicly disclosed |
| NovoSorb® MTX | Fully synthetic, membrane-free dermal matrix. Suits deep wounds, irregular geometries and highly exudative wounds. Can be used alone or layered with BTM. | Same surgical base plus clinicians treating chronic and deep wounds outside the operating theatre | FDA 510(k) 2 mm (2022); up to 6 mm (Mar 2025). TGA 2 mm (Mar 2025), 4/6 mm (May 2025). CDSCO India (Mar 2025). Health Canada (Apr 2025). Hong Kong registered in FY26. Commercial in 6 markets (Australia, US, Canada, Hong Kong, India, NZ). UK registration under way; EU MDR clearance targeted in FY27; Taiwan, Brazil and Mexico in progress. US launch Apr 2024; Australian launch 2025. | Per-unit device sales; prices not publicly disclosed. A new US HCPCS code application was being prepared (Jan 2026). |
| NovoSorb® SynPath® | NovoSorb®-based dermal matrix brand created for the US outpatient/physician-office setting. It holds an existing HCPCS code (A2006), which management calls the fastest route to outpatient reimbursement. | US outpatient wound-care clinicians (for example diabetic foot and venous leg ulcers), often in accounts that already use BTM as inpatients | US commercial launch planned for FY27 | Reimbursed under the CMS CY2026 flat-rate framework for 510(k) skin substitutes; product pricing not publicly disclosed |
| SUPRATHEL® (third-party, distribution only) | Synthetic resorbable skin substitute made by PolyMedics Innovations | Burn and wound clinicians in the UK, Australia and NZ | Exclusive distribution rights reported from May 2024 (secondary source; not re-verified in primary filings) | Distribution margin; terms not publicly disclosed |
Development pipeline and platform programs
| Program | Description | Status (latest disclosure) |
|---|---|---|
| BTM life-cycle innovation | Next-generation BTM aimed at shorter time-to-graft and shorter hospital length of stay | Active; part of the "indication-first" R&D approach under the new CSO (AR2026) |
| Novel NovoSorb® formulations | Platform innovations beyond BTM/MTX | Being prioritised under a new New Product Development and Portfolio Prioritisation framework (AR2026) |
| Hernia repair devices (historically "Syntrel") | Bioabsorbable hernia and tissue-reinforcement devices | Significant technical work and encouraging pre-clinical data, but management says industry dynamics have shifted and commercialisation options are under review (AR2026) |
| Plastics and reconstructive implantables (incl. breast reconstruction) | Implantable NovoSorb® structures | Under the same capital-allocation review as hernia (AR2026) |
| NovoSorb® Dermal Beta Cell Implant | Scaffold hosting pancreatic islets in the skin (type 1 diabetes cell therapy), partnered with Beta Cell Technologies Pty Ltd | Positive first-in-human proof of concept; PolyNovo supplying BTM for clinical trials (FY25 trading update) |
| Drug-elution depots | NovoSorb® as a drug carrier | Early stage (third-party profiles); no recent primary disclosure |
Financial Narrative
Income statement
Sources: FY22 results (26-Aug-2022: NPAT −A$1,192,532; FY22 revenue A$41.9m and sales A$37.6m per the AR2023 KPI panel); AR2023 (FY23); FY24 results (23-Aug-2024); FY25 results / Capital Brief; FY26 results presentation and AR2026. No dividend has been paid or recommended (AR2026). Market-data aggregator Stoxray shows "revenue" of A$41.4m (FY22), A$65.2m (FY23) and A$103.2m (FY24) because it excludes some other income; the company-reported totals above take precedence. FY23 non-commercial revenue is about A$6.9m and FY22 about A$4.3m (by subtraction).
Significant items reconciliation (FY26 presentation)
Margins and growth (computed on total revenue unless stated)
Revenue CAGR (computed). Total revenue grew at about 37.6% a year from FY22 (A$41.9m) to FY26 (A$150.0m). Commercial sales grew at about 38.5% a year (A$37.6m to A$138.4m). The FY24–FY26 two-year CAGR in commercial sales was about 22.6%.
Commentary.
Growth: Revenue has compounded at close to 40% a year over four years, but growth has slowed every year since FY23: sales growth went from 58.5% to 54.4% to 28.9% to 16.7% reported. Part of the FY26 slowdown is currency. Constant-currency growth was 21.3%, because the US dollar weakened against the Australian dollar over the year. The second half of FY26 (sales of about A$70.2m) was barely above the first half (A$68.2m). Management attributed 1H softness to temporary manufacturing output reductions and FX. Q1 FY26 had shown sales growth of 33.3% (A$34.7m), so 2H growth was well below 1H. On the August 2026 call management said July 2026 was a record sales month.
Gross margin: The company's margin measure (sales less change in finished goods and WIP) fell from 95.6% to 89.0%. Management attributes this to inventory movements during manufacturing optimisation. Output in 2H FY26 was 3.8 times 1H, and inventory fell from A$14.5m to A$9.8m. The underlying unit economics of a synthetic polymer device remain very attractive, but reported gross margin is now closer to 89%.
Operating leverage: Underlying EBITDA rose 50.4% on 16.7% sales growth. Underlying employee costs grew only 4.3% (excluding share-based payments), and underlying corporate and overhead costs fell 1.1% (excluding FX). The cost base of about 300 people is now absorbing growth. That is the main inflection of FY26.
Net profit: NPAT fell 44.5% to A$7.3m. FY25 was flattered by a A$5.7m tax benefit from recognising tax losses; FY26 carried a A$0.5m tax expense. FY26 also included a A$4.7m asset write-off from the R&D fire, offset by a A$6.0m insurance receipt, plus a A$2.7m unrealised FX loss.
R&D: R&D costs fell 36.9% to A$5.3m as the BARDA-funded pivotal trial completed. BARDA revenue is falling with it (A$8.6m to A$5.3m) and should approach zero.
Balance sheet: notes and sources
Sources: AR2023 KPI panel (FY22 and FY23 cash; the FY22 A$6.1m figure is taken from the KPI panel's paired label and should be treated with caution); FY24 results (A$45.9m); FY25 and FY26 presentations. FY26 borrowings were A$3.632m: an equipment finance facility of A$2.218m and an insurance premium funding facility of A$1.414m (AR2026). FY26 "Other" current assets include an insurance receivable of A$1.6m.
Cash flow
Sources: FY26 presentation (OCF, capex, FCF and debt repayment); FY25 OCF from the FY26 presentation comparative; FY24 OCF and FCF from FNArena (aggregator; secondary). FY26 capex was A$12.4m for completing the manufacturing facility and A$1.4m for rebuilding the R&D facility, which is covered by insurance. A further A$1.5m of machinery capex is payable in 1H FY27. FY26 OCF includes A$3.5m of insurance receipts. The FY26 cash bridge ran: opening A$33.5m, plus OCF A$23.1m, less capex A$13.8m, less debt repayment A$5.3m, less FX and other A$2.1m, giving closing cash of A$35.4m. Before that, the company raised about A$53m of equity in November 2022.
Commentary. FY26 was the first year of clear self-funding. Operating cash flow rose by A$20.0m on better working-capital management: receivables fell 9% and inventories fell 32% while sales grew 17%. With most of the manufacturing capex now spent, management expects cash to keep building in FY27 if trading continues as it is.
Ratios (computed unless stated)
Notes: interest expense was A$0.9m in both FY25 and FY26 (FY26 presentation).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
# Details
| # | Subsidiary | Role |
|---|---|---|
| 1 | PolyNovo Biomaterials Pty Limited | Australian proprietary company (technology/IP heritage) |
| 2 | NovoSkin Pty Ltd | Australian proprietary company |
| 3 | NovoWound Pty Ltd | Australian proprietary company |
| 4 | PolyNovo NZ Ltd | Trading/employment entity, New Zealand |
| 5 | PolyNovo UK Ltd | Trading/employment entity, UK |
| 6 | PolyNovo North America LLC | Trading/employment entity, US |
| 7 | PolyNovo Singapore Private Ltd | Trading/employment entity, Singapore |
| 8 | PolyNovo Ireland Ltd | Trading/employment entity, Ireland |
| 9 | PolyNovo Biomaterials India Private Ltd | Trading/employment entity, India |
| 10 | PolyNovo Hong Kong Ltd | Trading/employment entity, Hong Kong |
Products
| Product | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
NovoSorb BTM sales (AUD Mn) | — | 112.0 | 125.8 |
NovoSorb MTX sales (AUD Mn) | — | 6.7 | 12.6 |
Total NovoSorb commercial sales (AUD Mn) | 92.0 | 118.6 | 138.4 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
BTM YoY growth reported (%) | — | 12.3 |
BTM YoY growth constant currency (%) | — | 16.4 |
MTX YoY growth reported (%) | — | 89.6 |
MTX YoY growth constant currency (%) | — | 98.9 |
BTM share of commercial sales (%) | 94.4 | 90.9 |
MTX share of commercial sales (%) | 5.6 | 9.1 |
Products (Half-Yearly)
| Product | 1H FY2023 | 1H FY2024 | 1H FY2025 | 1H FY2026 |
|---|---|---|---|---|
NovoSorb BTM (AUD Mn) | 27.3 | 42.1 | 52.0 | 62.0 |
NovoSorb MTX (AUD Mn) | — | 0.1 | 2.1 | 6.2 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total revenue incl. BARDA and other income (AUD Mn) | 41.9 | 66.5 | 104.8 | 129.2 | 150.0 |
NovoSorb commercial sales (AUD Mn) | 37.6 | 59.6 | 92.0 | 118.6 | 138.4 |
BARDA revenue (AUD Mn) | — | — | — | 8.6 | 5.3 |
Other income (AUD Mn) | — | — | — | 2.0 | 6.3 |
Changes in inventories and WIP (COGS proxy, AUD Mn) | — | — | — | 5.2 | 15.2 |
Gross margin on company definition (%) | — | — | — | 95.6 | 89.0 |
Employee-related expenses (AUD Mn) | — | — | — | 74.5 | 78.8 |
R&D costs incl. clinical (AUD Mn) | — | — | — | 8.5 | 5.3 |
Corporate, admin and overhead (AUD Mn) | — | — | — | 29.9 | 34.5 |
EBITDA reported (AUD Mn) | — | — | 3.6 | 11.2 | 12.1 |
EBITDA underlying, before significant items (AUD Mn) | — | — | — | 8.9 | 13.4 |
Operating profit (AUD Mn) | — | — | — | 7.5 | 7.8 |
Income tax benefit (+) / expense (−) (AUD Mn) | — | — | — | 5.7 | -0.5 |
Net profit after tax (AUD Mn) | -1.2 | -4.9 | 5.3 | 13.2 | 7.3 |
Basic EPS computed (A cents) | — | — | — | 1.9 | 1.1 |
Dividends per share (A cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Item (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Reported EBITDA (AUD Mn) | 11.2 | 12.1 |
Add: write-off of assets from R&D fire (AUD Mn) | 0.0 | 4.7 |
Less: interim insurance claim (AUD Mn) | 0.0 | -6.0 |
Add: unrealised FX loss / less gain (AUD Mn) | -2.2 | 2.7 |
Underlying EBITDA (AUD Mn) | 8.9 | 13.4 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total revenue growth (%) | — | 58.8 | 57.5 | 23.3 | 16.1 |
Commercial sales growth (%) | — | 58.5 | 54.4 | 28.9 | 16.7 |
EBITDA margin on total revenue (%) | — | — | 3.4 | 8.7 | 8.1 |
Underlying EBITDA margin on commercial sales (%) | — | — | — | 7.5 | 9.7 |
Net margin (%) | -2.8 | -7.4 | 5.1 | 10.2 | 4.9 |
Gross margin on company definition (%) | — | — | — | 95.6 | 89.0 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD Mn) | 6.1 | 46.8 | 45.9 | 33.5 | 35.4 |
Trade and other receivables (AUD Mn) | — | — | — | 24.4 | 22.2 |
Inventories (AUD Mn) | — | — | — | 14.5 | 9.8 |
Other current assets (AUD Mn) | — | — | — | 4.7 | 6.5 |
Total current assets (AUD Mn) | — | — | — | 77.1 | 73.9 |
Total assets (AUD Mn) | — | — | — | 127.5 | 132.1 |
Total liabilities (AUD Mn) | — | — | — | 44.1 | 41.4 |
Net assets / total equity (AUD Mn) | — | — | — | 83.4 | 90.7 |
Total borrowings (AUD Mn) | — | — | — | — | 3.6 |
Net debt, negative = net cash (AUD Mn) | — | — | — | — | -31.8 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | — | — | 5.1 | 3.1 | 23.1 |
Capital expenditure (AUD Mn) | — | — | — | — | 13.8 |
Free cash flow, company definition (AUD Mn) | — | — | 2.2 | — | 9.4 |
Repayment of borrowings (AUD Mn) | — | — | — | — | 5.3 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE, NPAT / average equity (%) | — | 8.4 |
ROE, NPAT / closing equity (%) | 15.8 | 8.1 |
ROA, NPAT / average total assets (%) | — | 5.6 |
Asset turnover, total revenue / average total assets (x) | — | 1.16 |
Debt / equity (x) | — | 0.04 |
Net debt / EBITDA (x) | — | -2.6 |
Interest coverage, EBITDA / interest expense (x) | 12.4 | 13.4 |
Inventory days on commercial sales (days) | 44.6 | 25.8 |
Receivable days on commercial sales (days) | 75.1 | 58.5 |
Revenue by Region
| Region | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
United States sales (AUD Mn) | 31.9 | 46.1 | 68.7 | 88.4 | 102.1 |
Rest of World sales (AUD Mn) | 5.8 | 13.5 | 23.3 | 30.3 | 36.3 |
Total NovoSorb sales (AUD Mn) | 37.6 | 59.6 | 92.0 | 118.6 | 138.4 |
Region Margins & Growth (%) and Revenue by Region (%)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
US sales growth reported (%) | 44.5 | 49.0 | 28.7 | 15.6 |
ROW sales growth reported (%) | 132.8 | 72.6 | 30.0 | 20.0 |
US share of sales (%) | 77.3 | 74.7 | 74.5 | 73.8 |
ROW share of sales (%) | 22.7 | 25.3 | 25.5 | 26.2 |
Revenue by Region (FY2025–FY2026)
| Region | FY2025 | FY2026 |
|---|---|---|
Americas sales (AUD Mn) | 90.8 | 104.1 |
EMEA sales (AUD Mn) | 17.6 | 20.6 |
APAC sales (AUD Mn) | 10.2 | 13.7 |
Region growth (%)
| Region growth (%) | FY2026 reported (%) | FY2026 constant currency (%) |
|---|---|---|
Americas | 14.7 | 20.2 |
EMEA | 17.3 | 17.6 |
APAC | 33.6 | 37.8 |
Markets
| Market | FY26 growth disclosed | Basis | Source |
|---|---|---|---|
Turkey | 79.0% | constant currency | FY26 presentation |
India | 52.8% (cc); 35.4% (AUD) | cc / AUD | FY26 presentation; AR2026 |
Hong Kong | 49.9% (cc); 43.0% (AUD); 10 new hospital accounts | cc / AUD | FY26 presentation; AR2026 |
Ireland | 38.3% | constant currency | FY26 presentation |
Australia | 33.9% (cc); ANZ +26.0% (AUD) | cc / AUD | FY26 presentation; AR2026 |
DACH (Germany, Austria, Switzerland) | 15.5% | constant currency | FY26 presentation |
UK | 12.9% | AUD | AR2026 |
Taiwan | Fastest-growing APAC market (distributor-led) | qualitative | AR2026 |
Malaysia | First full year, ahead of plan with one representative | qualitative | AR2026 |
Share Price History
| Date | Price (AUD) | Context | Source |
|---|---|---|---|
24 May 2023 | 1.43 | — | Kalkine |
20 Oct 2023 | 1.12 | FY24 low | Motley Fool |
Jul 2024 | 2.59 | FY24 high | Motley Fool |
7 Mar 2025 | about 1.28–1.34 | CEO exit news | Capital Brief; People Matters |
14 May 2025 | 1.51 | — | FNArena |
30 Jul 2025 | 1.36 | After FY25 trading update | Kalkine |
27 Oct 2025 | 1.345–1.36 | Chair resigns | Business News Australia; Capital Brief |
24 Feb 2026 | 0.93 | After 1H FY26 results | Motley Fool data |
24 Sep 2026 | 0.98 | Latest verified close | Fintel |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | about A$677m | 0.98 × 690.84m |
Enterprise value | about A$645m | Market cap − cash A$35.4m + borrowings A$3.6m (leases excluded) |
P/E (FY26 statutory) | about 92x | NPAT A$7.3m |
EV/EBITDA (FY26 reported) | about 53x | EBITDA A$12.1m |
EV/EBITDA (FY26 underlying) | about 48x | Underlying EBITDA A$13.4m |
EV/Sales (FY26 commercial sales) | about 4.7x | A$138.4m |
EV/Revenue (FY26 total) | about 4.3x | A$150.0m |
P/B | about 7.5x | Net assets A$90.7m |
Broker / Aggregate Details
| Broker / aggregate | Rating | Target (AUD) | Date |
|---|---|---|---|
Consensus (Fintel average) | — | 1.28 (from 1.75 in Jun 2026; earlier 1.38) | Sep 2026 |
Macquarie | Outperform (maintained) | — | Jan, Feb and Jun 2026 |
Canaccord Genuity | Buy (maintained) | — | Feb 2026 |
Bell Potter | Buy (maintained) | — | Feb and Jul 2026 |
Evans & Partners | Speculative Buy | 2.65 | Oct 2025 |
Wilsons | — | 1.85 (cut from 3.00) | Mar 2025 |
Capital Markets
| Item | Detail |
|---|---|
Dividend history | None ever paid; none paid or recommended for FY26 (AR2026) |
Dividend policy | No formal policy; cash reinvested in growth |
Buybacks | None authorised or executed |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | A$3.632m total borrowings at 30 Jun 2026: equipment finance A$2.218m and insurance premium funding A$1.414m. A$5.3m of borrowings was repaid in FY26. |
Capital raising history | About A$53m equity raise in Nov 2022 (most recent) |
Analyst Conclusions
Management guidance
There is no quantitative FY27 guidance. The qualitative message is a focus on execution, record July 2026 sales, cash accumulation in FY27 if trends hold, and more operating leverage and profitability as the business scales. The five FY27 priorities are the PMA, the SynPath launch, MTX acceleration, innovation and business-development capability, and operating leverage.
Consensus expectations
A Simply Wall St narrative from August 2025 modelled revenue of about A$230.5m and earnings of about A$41.0m by FY28, implying about 21% annual revenue growth. Against the FY26 actual of A$150.0m, that path now looks demanding. The cut in the average price target to about A$1.28 suggests forecasts have been revised down since mid-2026.
Bull case
-
PMA as a step change. A successful PMA would give BTM an on-label US full-thickness burns indication, backed by what management describes as the most comprehensive Level 1 RCT in US dermal substitutes. It would also place BTM in the CMS OPPS PMA payment class (APC 6000) and support conversion of remaining allograft users.
-
Operating leverage is real. Underlying EBITDA rose 50.4% on 16.7% sales growth with flat headcount (about 301). BARDA trial costs are rolling off, and the new facility should restore gross margin toward the low-to-mid 90s per cent once fully validated. Free cash flow turned positive (A$9.4m) with most capex finished.
-
Optionality beyond burns. US non-burn indications are growing at a 52.8% three-year CAGR, and MTX nearly doubled to A$12.6m. SynPath opens a US outpatient market that CMS has repriced to the disadvantage of high-cost biologics. Platform licensing (implantables, cell-therapy scaffolds) is unpriced at about 4.7x EV/sales.
Bear case
-
Growth is decelerating structurally. Reported sales growth slowed from 54% to 29% to 17% over three years, and 2H FY26 sales (about A$70.2m) were nearly flat on 1H (A$68.2m). Burns volumes are lumpy, and the US sales force (106) is now large enough that productivity gains, not headcount, must drive growth.
-
Execution risk is concentrated. About 91% of sales come from one product, from one manufacturing site that already disrupted 1H FY26 results, in one main market (74% US) exposed to FX and tariffs. The PMA timeline has already slipped once, and FDA review of a novel synthetic Class III submission could take longer than expected.
-
The reimbursement environment is unsettled. CMS has said it may bundle skin substitutes into procedure payments and differentiate rates after reviewing 2026 claims. That could compress the outpatient opportunity before SynPath scales, while biologic incumbents compete hard on price.
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| 29 Oct 2026 | FY26 AGM: remuneration report vote, first AGM under Chair Hoare, possible trading commentary |
| Oct–Nov 2026 | Q1 FY27 trading update (if continued): constant-currency growth versus the about 21% FY26 run-rate; MTX trajectory |
| Before 31 Dec 2026 | BTM PMA submission to the FDA |
| Nov 2026 | CMS CY2027 PFS/OPPS final rules: any bundling or differentiated skin-substitute payments |
| 1H FY27 | Remaining insurance recoveries; R&D Innovation Centre rebuilt and back in use |
| FY27 | SynPath US launch and early outpatient uptake; CMS coding decisions for BTM and MTX |
| FY27 | Regulatory validation of and transition to the new manufacturing facility; gross-margin recovery |
| FY27 | UK and EU MDR clearance for MTX; Japan regulatory progress; Mexico and Brazil registrations |
| Feb 2027 | 1H FY27 results: operating leverage, FCF, first disclosures under the new LTI framework |
| FY27 | Any business-development or licensing transaction for non-core NovoSorb® programs |
| Ongoing | Substantial-holder register changes (FIL, State Street, Vanguard) and director dealings |
Analyst verdict
PolyNovo enters FY27 as a better-governed, cash-generative and more professionally run company than it was 18 months ago, yet its share price is well below where it was then. The 2025 governance crisis has been addressed: there is a new Chair, three new directors, separate committees and an executive team heavily recruited from CSL. FY26 showed that the business model works at scale. Sales reached A$138.4m, underlying EBITDA rose 50% to A$13.4m, free cash flow was positive and the balance sheet is essentially debt-free. The technology still stands apart. A fully synthetic dermal matrix with infection resilience, a large and mostly independent evidence base, and a cost structure that suits CMS's move away from paying premiums for biologics is unusual in wound care.
The market is nonetheless right to discount the story. Reported growth has slowed sharply, and FY26 second-half sales barely grew on the first half. The FY26 gross-margin dip and the 1H profit collapse showed how much a single-site manufacturer depends on operations. The PMA, the main de-risking event, has already slipped once. At about 48x underlying EBITDA and about 4.7x EV/sales, the valuation still implies growth returning to above 20% with margin expansion, so the business needs to execute on several fronts at once.
Our synthesis is that PolyNovo has become an execution story with one binary catalyst (PMA filing, then approval) and one structural question (whether outpatient reimbursement turns SynPath into a second growth engine rather than a cost centre). The PMA submission before December 2026 and constant-currency growth staying at or above about 20% are the two tests that matter most. If both are met, the current price leaves meaningful upside. If either is missed, the shares are likely to keep trading on a "show-me" basis. On balance the risk/reward looks positive but conditional.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Joined / tenure | Prior roles | Education |
|---|---|---|---|---|
Bruce Peatey | Chief Executive Officer | Dec 2025 | Led the US, Canada and Latin America businesses at Dentsply Sirona (about US$1.3bn operation); earlier Asia Pacific region lead; Abbott, Baxter, Biosensors International | BAppSc, MBA |
Jan Gielen | Chief Financial Officer | Dec 2018 | CFO of CardioScan (6 years); Finance Director of ICIX (Silicon Valley); Pitcher Partners | BBus (Acc), CA |
Ed Graubart | President, North America | 2019; President since Mar 2024 | EBI (Biomet), DePuy Spine (J&J), NuVasive, Ceterix Orthopedics, Titan Spine | BSc |
Dr Marthe D'Ombrain | Chief Scientific Officer | Jun 2026 | CSL Executive Director & Head, Global Research Innovation; NED of AusBiotech | PhD (WEHI / University of Melbourne), GAICD |
Allison Myers | Chief Quality and Regulatory Affairs Officer | Joined Oct 2025 as VP Quality; promoted Feb 2026 | 28 years at GSK (Australia and UK), including Site Director, GSK Melbourne | BSc (Pharmacology), BSc (Hons) |
Amy Demediuk | General Counsel and Company Secretary | Feb 2026 | CSL General Counsel (Global R&D and Strategy), 16+ years at CSL; Arnold Bloch Leibler | LLB (Hons), MIPL, GradDipACG |
Kimberley Axon | Chief People Officer | Mar 2025 | CPO at Dubber; I-MED Radiology; Sage; Weatherford | BPsych (Hons) |
Tyson Parker | Chief Manufacturing and Supply Chain Officer | Sep 2026 | Senior manufacturing leadership at CSL Seqirus | BSc (Biological Science), MBA |
Board of Directors
| Director | Role | Appointed | Committees | Background |
|---|---|---|---|---|
Leon Hoare | Non-Executive Chair | Director 27 Jan 2016; Chair from 27/28 Oct 2025 | Chair, Nominations | Former MD of Lohmann & Rauscher ANZ (to Dec 2025); 24 years at Smith & Nephew, including President Asia-Pacific Advanced Wound Management; NED of Medical Developments International (ASX: MVP) |
Robert Douglas | Independent NED | 14 Oct 2025 | Audit & Risk | ResMed President and COO 2013–2023; Globus Medical (NYSE: GMED) board and audit committee |
Dr Robyn Elliott | NED | 28 Oct 2019 (Acting CEO 11 Mar 2025 to 1 Dec 2025) | Remuneration; Audit & Risk | Global Head, Strategic Portfolio Management at CSL Behring; former MD of IDT Australia |
Christine Emmanuel-Donnelly | Independent NED | 13 May 2020 | Chair, Remuneration; Nominations | IP and business development executive; former CSIRO Executive Manager BD; Chair of Impedimed (ASX: IPD); MVP board |
Dr Charmaine Gittleson | Independent NED | 1 Apr 2026 | Remuneration; Nominations | Former CSL Chief Medical Officer; Chair of Percheron Therapeutics; NED of Imugene and George Medicines |
Andrew Lumsden | Independent NED | 4 Jun 2021 | Chair, Audit & Risk; Nominations | Former CEO, CFO and COO of Wellcom Worldwide Australasia; ex-PwC |
David Williams (former) | Former Chair | Director 28 Feb 2014; resigned 27 Oct 2025 | — | Held 21,655,000 shares at cessation |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Mar 2025 | Kimberley Axon appointed CPO | People and culture build-out |
7–11 Mar 2025 | CEO Swami Raote asked to leave, then steps down immediately; Robyn Elliott Acting CEO | Followed media reports of an independent investigation into alleged bullying of senior executives (including Raote and CFO Gielen) by Chair Williams. Shares fell about 13% on 7 Mar 2025 and were about 40% below 24 Feb 2025 levels by mid-March (Stockhead). |
Mar 2025 | Spencer Stuart engaged to review board structure, skills and composition | Governance remediation |
Oct 2025 | Kingston Reid engaged for board training on workplace behaviour; former Westpac chair Lindsay Maxsted engaged to advise on governance matters | Disclosed the day before the Chair resigned (Capital Brief) |
14 Oct 2025 | Rob Douglas joins board | Board renewal |
Oct 2025 | Bruce Peatey named CEO (starts 1 Dec 2025) | Ends an eight-month interim period |
27 Oct 2025 | David Williams resigns as Chair after 11 years; Leon Hoare becomes Chair | Shareholder push-back ahead of the 28 Oct 2025 AGM; re-election resolution withdrawn |
Feb 2026 | Amy Demediuk (GC & CoSec) joins; Allison Myers promoted | Compliance and quality strengthening ahead of the PMA |
1 Apr 2026 | Charmaine Gittleson joins board | Clinical and regulatory board skills |
1 Jun 2026 | Marthe D'Ombrain becomes CSO | R&D reprioritisation |
Sep 2026 | Tyson Parker joins as CMSCO | Manufacturing scale-up and inspection readiness |
Major Shareholders
| Holder | Shares | % voting power | As at | Source |
|---|---|---|---|---|
FIL Limited (Fidelity International) | 59,701,782 | 8.64 | Jun 2026 | Substantial holder notice (FilingReader) |
State Street Corporation | 41,858,253 | 6.06 | 26 Aug 2025 (may have changed) | Substantial holder notice (FilingReader) |
The Vanguard Group | 34,514,142 | 5.00 | 18 Jun 2024 (may have changed) | Substantial holder notice (TipRanks) |
David Williams (former Chair) | 21,655,000 | about 3.1 (computed) | 27 Oct 2025 (holding at cessation) | AR2026 |
UBS Group AG | below 5% | — | Ceased 18 May 2026 | FilingReader |
Unnamed new substantial holder | — | ≥5 | 25 Jun 2026 notice | InvestSMART announcements list |
Competitive Landscape
Key Competitors
| Competitor | Competing products | Segment overlap | Positioning vs PolyNovo |
|---|---|---|---|
Integra LifeSciences (NASDAQ: IART) | Integra Dermal Regeneration Template ("Integra Skin"), PriMatrix, MediHoney | Dermal templates for burns and reconstruction (the closest substitute) | Incumbent bovine collagen-GAG template with long PMA history; has suffered quality remediation and supply constraints in 2024–2025 |
AVITA Medical (NASDAQ: RCEL / ASX: AVH) | RECELL (autologous cell harvesting), Cohealyx, PermeaDerm | Burns and trauma centres | Often used alongside dermal matrices rather than instead of them; also a competitor for burn-centre budgets |
Organogenesis (NASDAQ: ORGO) | Apligraf, Dermagraft, PuraPly, Affinity, NuShield | Advanced wound care, mainly outpatient chronic wounds | Large outpatient incumbent; heavily exposed to the 2026 CMS reset |
MiMedx Group | Placental and amniotic allografts (EPIFIX etc.) | Outpatient chronic wounds, surgical | Biologic allografts reimbursed in the 361 HCT/P class |
Smith+Nephew | Grafix, PICO negative-pressure therapy, wound biologics | Advanced wound management | Diversified wound-care major; Chair Hoare is a former S&N executive |
Kerecis (Coloplast) | Intact fish-skin grafts | Burns, trauma, chronic wounds | Biologic xenograft; well capitalised under Coloplast |
Vericel | Epicel, NexoBrid (enzymatic debridement) | Large burns | Complementary or competitive in burn-centre workflows |
MedSkin Solutions Dr. Suwelack | MatriDerm (collagen-elastin matrix) | Dermal templates, mainly Europe | Biologic template competitor in EMEA |
PolyMedics Innovations | SUPRATHEL | Burns (partial thickness) | Both a competitor and a distribution partner in the UK/ANZ |
Cadaveric allograft suppliers (for example MTF Biologics, tissue banks) | Temporary allograft skin cover | Large burns | The main incumbent practice that a BTM PMA aims to displace |
Mölnlycke, Convatec, 3M/Solventum | Dressings and negative-pressure therapy | Wound management adjacent | Adjacent; compete for wound-care budgets |
Peer Comparison FY2025
| Company | Latest FY | Revenue | YoY growth (%) | Margin metric | R&D intensity |
|---|---|---|---|---|---|
PolyNovo | FY26 (Jun-26) | A$150.0m total; A$138.4m sales | 16.1 (21.3 cc on sales) | Gross margin 89.0%; EBITDA margin 8.1% on total revenue; NPAT A$7.3m | 3.5% (income-statement R&D only) |
Integra LifeSciences | FY25 (Dec-25) | US$1,635.2m | 1.5 (organic −0.7) | Adjusted EBITDA margin 19.4% | — |
Organogenesis | FY25 (Dec-25) | US$563.0m net product revenue | 17 | Gross margin 76%; guides FY26 revenue down 25–38% | — |
AVITA Medical | FY25 (Dec-25) | US$71.6m | 11 | Gross margin 82.1%; net loss US$48.6m | — |



